Dosage recommendations not available for pediatric patients with renal impairment.Hemodialysis removes approximately 30–40% of a dose of piperacillin/tazobactam (see Special Populations under Pharmacokinetics); supplemental dose of the drug needed after each hemodialysis session....
Renal excretion of piperacillin/tazobactam accounts for approximately 50 to 60% of the administered dose, and biliary excretion for a considerably smaller part (2%). The elimination half-lives of tazobactam and piperacillin after single- or multiple-dose administration range from 0.78 to 0.91 hours. ...
Piperacillin/tazobactam is a β-lactam/β-lactamase inhibitor combination with a broad spectrum of antibacterial activity encompassing most Gram-po
Piperacillin/tazobactam: Delirium (first report) in a patient with end-stage renal disease: case report
(100 mg piperacillin and 12.5 mg tazobactam) every 8 (eight) hours 112.5 mg/kg(100 mg piperacillin and 12.5 mg tazobactam) every 6 (six) hours Pediatric patients weighing over 40 kg and with normal renal function should receive the adult dose [see Dosage and Administration (2.1, 2.2)]. ...
against a wider spectrum of bacteria. Piperacillin is administered as an intravenous (IV) or intramuscular (IM) injection and is used to treat various types of serious infections caused by susceptiblestrainsof bacteria. Piperacillin is often used in combination with tazobactam, another type of ...
Piperacillin-tazobactam can be neurotoxic, especially in the setting of renal impairment, although to a lesser degree than penicillin. It is primarily excreted as unchanged drug in the urine. Its clearance is directly proportional to renal function and must therefore be dose adjusted in renal ...
Blinded dose adjustment was made for patients receiving meropenem-vaborbactam and with estimated creatinine clearance less than 50 mL/min (not needed for patients receiving piperacillin-tazobactam). Randomization was stratified by geographic region (defined as North America, Europe, Asia Pacific, and ...
摘要: The article describes the case of a patient with acute lymphoblastic leukemia (ALL) who developed acute renal failure during treatment with methotrexate and piperacillin/tazobactam.年份: 2012 收藏 引用 批量引用 报错 分享 全部来源 求助全文 EBSCO 相似文献Methotrexate/piperacillin/tazobactam Author ...
Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly prescribed in the intensive care unit setting. Admitted patients often show large variability in treatment response due to multiple pathophysiological changes present in this population that alter the drug’s pharmacokine...